Cannabis acquisition financing options

What financing is actually available to buy a cannabis business?

Six sources fund nearly every licensed cannabis acquisition: the buyer’s own cash, a seller note, private credit from a cannabis-focused lender, a sale-leaseback of real estate, equipment financing, and outside equity from private investors or family offices. SBA loans and conventional bank acquisition loans are not on the list. SBA SOP 50 10 8, effective 1 June 2025, excludes any business that grows, processes, distributes, or sells marijuana, and the reasons banks stay out are covered in why SBA and banks are unavailable.

Debt dominates what capital there is. The Viridian Cannabis Deal Tracker, as reported by MJBizDaily, put debt at about 94.8% of all capital raised by U.S. licensed operators in 2025, with most of it refinancing existing loans rather than funding growth. That is the market a buyer walks into: equity is scarce, institutional debt is expensive and selective, and the seller is often the most willing lender in the room.

Sources of capital compared

The figures below are dated and sourced where a public number exists. Where no reliable public figure exists, the table says so rather than guessing. Lenders are named only because they publish filings; none is a partner of this site.

Source	Indicative cost	Speed	Collateral	Who qualifies
Buyer cash or equity	No coupon; the cost is dilution or opportunity cost	Immediate	None	Anyone who passes the state’s owner vetting and can document source of funds
Seller note	General small-business notes run 6% to 10% (Morgan & Westfield data via Iconic, Aug 2026); cannabis notes are negotiated deal by deal	Fastest: no outside underwriter	Pledge of equity, equipment, real estate, guaranties; rarely the licence itself	Buyers the seller trusts, with a real down payment
Private credit (cannabis lenders)	Portfolio yields of 13.2% (AFC, 30 June 2026) to 15.8% (Chicago Atlantic REFI, 30 June 2026)	Weeks of diligence	First lien on real estate, equipment, receivables, equity pledges	Established operators; public lenders target loans of $10 million to $60 million
State-chartered banks and credit unions	No reliable public rate series; priced below private credit	Slow; heavy compliance onboarding	Real estate first, low loan-to-value	Operators with clean compliance files, usually for real estate rather than goodwill
Sale-leaseback	Rent set as a yield on the purchase price; see the sale-leaseback page	60 to 120 days is typical for a real estate closing	The building itself; long lease with guaranties	Owners of cultivation, processing, or retail property with a creditworthy tenant
Equipment financing	Priced by lessor; no public benchmark	Days to weeks	The equipment (purchase-money lien)	Operators buying new, resaleable equipment
Family office or private investor equity	Target returns above lender yields; control terms matter more than the rate	Months	None, but governance rights	Deals in limited-licence states with clean books

Each row has its own page: private credit, seller financing, equipment financing, and family-office capital. Current pricing detail sits on cannabis loan terms and rates.

Seller financing vs private credit vs sale-leaseback

These three do different jobs, and the right choice depends on what the target owns and how big the deal is.

Seller financing fits almost every deal under about $10 million, because institutional lenders rarely write loans that small. Chicago Atlantic’s August 2026 investor presentation describes a target loan size of $10 million to $60 million and an average loan of $18.1 million. A $2 million dispensary purchase is simply not their product. The seller already knows the business, accepts its risk, and can close on the deal’s timetable.

Private credit fits larger platforms and buyers with hard collateral. The same presentation shows what lenders want: senior debt under 2.0x EBITDA, a weighted average loan-to-enterprise-value of 46.0%, and real estate collateral coverage of 1.2x (30 June 2026). A buyer who cannot show those ratios after the acquisition will not get a term sheet, whatever rate they offer to pay.

Sale-leaseback fits targets that own their building. It converts real estate into cash at closing in exchange for a long lease, and it is not debt on the balance sheet. But the rent is a fixed claim that survives bad years. Tenant stress is visible in public filings: Innovative Industrial Properties’ second-quarter 2026 report describes defaulted tenants, security deposits applied to unpaid rent, and a tenant receivership expected to run through the end of 2026. A lease you cannot afford in a price-compressed market is as dangerous as a loan you cannot service.

Question	Seller note	Private credit	Sale-leaseback
Works for deals under $5 million?	Yes	Rarely	Only if real estate is owned
Needs owned real estate?	No	Strongly preferred	Yes
Outside diligence?	Light	Heavy	Moderate, property-focused
Prepayment flexibility	Usually open	Make-whole or prepayment fees are standard	None; it is a lease
Regulator disclosure	Seller is often already vetted	Lender may be a financial interest holder	Landlord disclosed if rent shares profit

How much debt can a cannabis acquisition carry?

Less than the same cash flow would carry in another industry, because federal tax comes first. Adult-use operators still cannot deduct ordinary operating expenses under 280E, so taxable income is far higher than book profit. Viridian’s deal tracker commentary treats more than 3x debt to EBITDA as unsustainable while 280E applies, and not much above 4x as safe even without it. Size debt to cash flow after tax, not to EBITDA.

Illustrative stack. A buyer pays $4.0 million for a dispensary producing $1.0 million of adjusted EBITDA and about $300,000 of cash income taxes, leaving $700,000 before debt service.

1. Buyer cash: $1.4 million (35%).
2. Seller note: $1.0 million (25%) at 9%, fully amortising over 5 years. Payment is about $20,760 a month, or $249,100 a year.
3. Senior private loan: $1.6 million (40%) at 14%, interest-only. Interest is $224,000 a year.

Total debt service is about $473,100 against $700,000 of after-tax cash flow, a coverage ratio of roughly 1.48x. Total debt is 2.6x EBITDA. Drop revenue 15% in a price-compressed market and that cushion disappears quickly, which is why many buyers push for a longer amortisation on the seller note or an earn-out in place of part of the fixed debt. In practice a $1.6 million senior loan is below most institutional minimums, so in a deal this size the senior piece often comes from a private individual lender or is replaced by more seller paper.

Financing has to clear the regulator too

A cannabis loan is not only a credit decision. Many states treat people who fund a licensee as parties the regulator must know about. California’s 4 CCR 15004 lists a person providing a loan to the business as a financial interest holder who must be disclosed, while exempting banks and financial institutions and holders of a mere security interest in property. Washington’s WAC 314-55-035 requires licensees to disclose the source of all funds, including money from financiers, before it is invested, and bars a financier from taking revenue share or control without approval. The wider framework is explained in true party of interest and financial interest rules.

The practical points:

• Put every capital source in the change-of-ownership application, not just the buyer entity.
• Avoid loan terms that look like ownership: profit participation, board control, or conversion rights can turn a lender into an owner who needs full vetting.
• Expect the lender’s default remedies to be limited. A lender generally cannot simply take over a licence; it needs regulator approval or a receiver.

Does rescheduling change the financing picture?

Only at the edges so far. The April 2026 order moved FDA-approved products and marijuana under a state medical licence to Schedule III; adult-use marijuana remains Schedule I. For qualifying medical activity, relief from 280E improves after-tax cash flow, which is what debt is sized on. It did not rewrite SBA eligibility text or FinCEN’s 2014 banking guidance, and the SAFE Banking Act of 2026 remains introduced, not enacted. Chicago Atlantic’s management told investors in August 2026 that its lending business does not depend on those changes. Underwrite the deal on today’s rules.

This is educational material, not legal, tax, or investment advice, and nothing here is a commitment to lend or a promise that financing will be available. If you want to talk through how a specific purchase might be funded, you can book a confidential intro call.